Achieve Life Sciences Inc. (ACHV)
Achieve Life Sciences: Thesis Intact, Setup Remains Constructive (Rating Downgrade)
Achieve Life Sciences is rated a 'buy' as it nears a second NDA resubmission after resolving prior manufacturing issues. ACHV's FDA setback was manufacturing-related, not efficacy or safety, with two successful Phase 3 trials and over 1,500 exposures supporting its profile. ACHV is well-capitalized, holding $188 million in cash post-private placement, sufficient to fund the NDA resubmission and initial launch activities.
Achieve Life Sciences: A Funded Manufacturing Reset, Not A Broken Clinical Thesis
Achieve Life Sciences is navigating a manufacturing reset for cytisinicline following a Complete Response Letter citing facility compliance, not efficacy or safety concerns. I remain bullish on ACHV, contingent on resolving manufacturing issues and leveraging a funded transition to commercialization, not market expansion or first-line displacement. ACHV's cash runway, bolstered by $180M upfront financing, appears sufficient through potential FDA approval in 1H 2027, but dilution and arbitration risks must be monitored.
Achieve Life Sciences Stockholders Weigh Board Slate, Share Increase at Annual Meeting
Achieve Life Sciences NASDAQ: ACHV held its 2026 Annual Meeting of Stockholders virtually, with Chief Executive Officer Andrew Goldberg serving as chairperson of the meeting. Goldberg called the meeting to order and said Erik Atkisson, the company's Chief Legal Officer, would act as secretary and record the minutes.
Achieve Life Sciences, Inc. (ACHV) Q1 2026 Earnings Call Transcript
Achieve Life Sciences, Inc. (ACHV) Q1 2026 Earnings Call Transcript
Achieve Life Sciences Q1 Earnings Call Highlights
Achieve Life Sciences NASDAQ: ACHV used its first-quarter 2026 earnings call to outline a transition period marked by new leadership, a major financing, manufacturing changes tied to its cytisinicline regulatory timeline and preparations for a potential commercial launch in 2027.
Achieve Life Sciences: The Recent Sell Off Skews The Outcomes
Achieve Life Sciences is rated Buy for risk-tolerant investors after a sharp sell-off tied to FDA manufacturing concerns. Cytisinicline demonstrates strong efficacy and a superior safety profile versus Chantix, supporting blockbuster potential in smoking cessation. Manufacturing issues prompted a supplier switch to Adare Pharma; FDA approval probability is estimated at 35% on the first try, rising to 70% if resubmitted.
Achieve Life Sciences: Maintaining 'Buy' On Upcoming PDUFA And Expansion Into Vaping Cessation
Achieve Life Sciences remains a 'Buy' as cytisinicline's NDA for smoking cessation is under FDA review with a PDUFA date of June 20, 2026. ACHV exceeded long-term safety study requirements and secured a manufacturing partnership, positioning for a potential 1H 2027 commercial launch if approved. The company plans to initiate the phase 3 ORCA-V2 trial for vaping cessation in 1H 2026, targeting a large, underserved market segment.
Achieve Life Sciences (NASDAQ:ACHV) Share Price Crosses Above 200 Day Moving Average – Time to Sell?
Achieve Life Sciences, Inc. (NASDAQ: ACHV - Get Free Report) shares passed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $4.24 and traded as high as $4.37. Achieve Life Sciences shares last traded at $4.14, with a volume of 530,131 shares changing hands. Analyst Ratings Changes
Achieve Life Sciences: A Binary Bet With Cytisinicline And A Potential 2026 Launch
Achieve Life Sciences is a single-asset microcap centered on cytisinicline, with an accepted NDA and a June 20, 2026, PDUFA. Cytisinicline's α4β2 partial agonism aims to reduce cravings and blunt nicotine reward. In fact, the most promising aspect of cytisinicline was that its Phase 3 ORCA trials showed strong quit-rate deltas versus placebo.
Achieve Life Sciences: Could Be The Best 'Tobacco' Stock For 2026 - Strong Buy
Achieve Life Sciences is a late-stage Pharma company awaiting FDA approval for Cytisinicline, a novel (though proven) smoking cessation therapy, with a decision expected in June. Cytisinicline demonstrates superior efficacy and safety versus current treatments, with strong precedent in Europe and a large, underserved U.S. market. ACHV's market cap (~$250M) is a fraction of its potential, with peak sales for smoking and vaping cessation possibly reaching $2–3 billion.
Achieve Life Sciences, Inc. (ACHV) Q3 2025 Earnings Call Transcript
Achieve Life Sciences, Inc. ( ACHV ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Nicole Jones Richard A. Stewart - CEO & Executive Director Jaime Xinos - Chief Commercial Officer Mark Oki - Chief Financial Officer Jerry Wan - VP of Finance & Principal Accounting Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Gary Nachman - Raymond James & Associates, Inc., Research Division Brandon Folkes - H.C.
Achieve Life Sciences, Inc. (ACHV) Q2 2025 Earnings Call Transcript
Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q2 2025 Earnings Call August 7, 2025 8:30 AM ET Company Participants Cindy Jacobs - Former President & Chief Medical Officer Jaime Xinos - Chief Commercial Officer Mark K. Oki - Chief Financial Officer Nicole Jones - Corporate Participant Richard A.
